Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean patients with triple-negative breast carcinoma

HS Kim, SI Do, DH Kim, S Apple - Anticancer Research, 2020 - ar.iiarjournals.org
Background/Aim: The clinicopathological and prognostic significances of programmed death
ligand 1 (PD-L1) expression in triple-negative breast carcinoma (TNBC) are still unclear. We …

Clinicopathological and prognostic significance of programmed death ligand-1 SP142 expression in 132 patients with triple-negative breast cancer

J Chu, MK Yeo, SH Lee, MY Lee, SW Chae, HS Kim… - in vivo, 2022 - iv.iiarjournals.org
Abstract Background/Aim: The prognostic value of programmed death ligand-1 (PD-L1)
expression in triple-negative breast cancer (TNBC) has not been sufficiently investigated. In …

[HTML][HTML] High PD-L1 expression is closely associated with tumor-infiltrating lymphocytes and leads to good clinical outcomes in Chinese triple negative breast cancer …

NJ AiErken, H Shi, Y Zhou, N Shao… - … journal of biological …, 2017 - ncbi.nlm.nih.gov
Background: To investigate the role of Programmed death ligand 1 (PD-L1) expression and
tumor-infiltrating lymphocytes (TILs) in tumor recurrence and metastasis of Chinese patients …

Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer

Y Zeng, CL Wang, J Xian, Q Ye, X Qin… - OncoTargets and …, 2019 - Taylor & Francis
Purpose Tumors with high mutation load tend to have a stronger immune response in some
tumors. The correlation between expression of programmed death ligand-1 (PD-L1), a …

[HTML][HTML] Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer

M Li, A Li, S Zhou, Y Xu, Y Xiao, R Bi, W Yang - BMC cancer, 2018 - Springer
Background Programmed cell death ligand 1 (PD-L1) is a potential predictive biomarker of
the response to anti-PD-L1/anti-programmed cell death 1 (PD-1) therapy in multiple cancers …

Concordance of PD-L1 expression in triple-negative breast cancers in Chinese patients: A retrospective and pathologist-based study

C Chen, X Ma, Y Li, J Ma, W Yang, R Shui - Pathology-Research and …, 2022 - Elsevier
Objective To compare the expression of programmed cell death ligand 1 (PD-L1) in different
paraffin blocks from the same triple-negative breast cancers (TNBC) specimen and between …

[HTML][HTML] Overexpression of programmed death-ligand 1 receptor mRNA as an independent negative prognostic factor for triple negative breast cancer

I Purwanto, DS Heriyanto, A Ghozali… - World journal of …, 2020 - ncbi.nlm.nih.gov
Background Triple negative breast cancer (TNBC)(represents roughly 25% of all breast
cancers in Yogyakarta) still has the worst survival compared to other breast cancer subtypes …

[HTML][HTML] Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer

K Yoshikawa, M Ishida, H Yanai, K Tsuta, M Sekimoto… - Plos one, 2021 - journals.plos.org
Background Triple-negative breast cancer (TNBC) is the most aggressive type of breast
cancer. A recent study demonstrated the efficacy of anti-PD-L1 (anti-programmed death …

Differential prognostic impact of strong PD-L1 expression and 18F-FDG uptake in triple-negative breast cancer

SH Choi, JS Chang, JS Koo, JW Park… - American Journal of …, 2018 - journals.lww.com
Objectives: Triple-negative breast cancers (TNBC) is an aggressive disease and often
associated with early distant metastases, which negate the role of adjuvant radiotherapy. We …

[HTML][HTML] Correlation between the expression of PD-L1 and clinicopathological parameters in triple negative breast cancer patients

R Doğukan, R Uçak, FM Doğukan, C Tanık… - European journal of …, 2019 - ncbi.nlm.nih.gov
Objective Triple-negative breast cancer (TNBC) is a heterogenous group of tumors with no
estrogen receptor (ER), progesterone receptor (PR) and Cerb-B2/HER2 expression …